Tamara van Donge

Key components for antibiotic dose optimization 57 3 57. Van Donge T, Mian P, Tibboel D, Van Den Anker J, Allegaert K. Drug metabolism in early infancy: opioids as an illustration. Expert opinion on drug metabolism & toxicology. 2018;14(3):287-301. 58. Trivedi A, Lee RE, Meibohm B. Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert review of clinical pharmacology. 2013;6(2):159-170. 59. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clinical infectious diseases. 1998;27(1):23-27. 60. Allou N, Bouteau A, Allyn J, et al. Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. Annals of Intensive Care. 2016;6:106. 61. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clinical infectious diseases. 2005;40(Supplement_2):S99-S104. 62. MacGowan A. Elements of design: The knowledge on which we build. Clinical Microbiology and Infection. 2004;10(s2):6-11. 63. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of’bug and drug’. Nature Reviews Microbiology. 2004;2(4):289. 64. Álvarez R, Cortés LEL, Molina J, Cisneros JM, Pachón J. Optimizing the clinical use of vancomycin. Antimicrobial agents and chemotherapy. 2016;60(5):2601-2609. 65. Zeitlinger MA, Dehghanyar P, Mayer BX, et al. Relevance of Soft-Tissue Penetration by Levofloxacin for Target Site Bacterial Killing in Patients with Sepsis. Antimicrobial Agents and Chemotherapy. 2003;47(11):3548-3553. 66. Forrest A, Nix DE, Ballow CH, Goss TF, BirminghamM, Schentag J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial agents and chemotherapy. 1993;37(5):1073- 1081.